Life Style

Vaccine maker BioNTech to use mRNA tech behind its COVID-19 vaccine to target malaria

Pharmaceutical company BioNTech said Monday that it wants to use the mRNA technology behind its coronavirus vaccine to target malaria.

The Germany-based company, which developed the first widely approved coronavirus shot together with US partner Pfizer, aims to begin clinical trials for a “safe and highly effective malaria vaccine” by the end of next year.

BioNTech said it is also seeking to establish an mRNA vaccine production facility in Africa, which is among the regions that have struggled to get sufficient supply of COVID-19 vaccine doses.

For the latest headlines, follow our Google News channel online or via the app.

The company said it is working with partners to “evaluate how to establish sustainable mRNA manufacturing capabilities on the African continent to supply African countries with vaccines.” Once built, such a facility would be able to make various mRNA-based vaccines.

BioNTech and Pfizer have said they will deliver 1 billion doses of their COVID-19 vaccine to middle- and low-income countries this year, and another billion doses in 2022.

Last week, the two companies announced that a South African firm, the Biovac Institute, will become the first on the continent to start producing their coronavirus vaccine.

BioNTech has previously said it is working on a vaccine candidate for tuberculosis, with clinical trials aimed for 2022, and therapies for several forms of cancer.

Read more:

WHO warns fight against malaria could be set back 20 years

Pfizer says COVID-19 vaccine highly effective against Delta variant

BioNTech founder says Europe will reach herd immunity against COVID-19 this summer

Related Articles